CLAIMS

What is claimed is:

1. A modified cell comprising a modification in the TRAC or TRBC gene made by delivering a non-viral RNP complex comprising an *S. aureus* Cas9 polypeptide and a gRNA molecule that targets T cell receptor alpha (TRAC) or T cell receptor beta (TRBC), wherein the gRNA molecule comprises a targeting domain comprising a sequence that is the same, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.
2. A modified cell comprising a modification in the TRAC or TRBC gene made by delivering a non-viral RNP complex comprising an *S. aureus* Cas9 polypeptide and a gRNA molecule, wherein the complex localizes to a site in the TRAC or TRBC locus, which site comprises a target domain and an NNGRR sequence, wherein the gRNA molecule comprises a targeting domain comprising a sequence that is the same, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.
3. The modified cell of claim 1 or claim 2, wherein the gRNA molecule comprises a targeting domain comprising a sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.
4. The modified cell of claim 1, wherein the modification comprises a deletion or mutation of all or part of the TRAC or TRBC gene.
5. The modified cell of claim 1, said modified cell further comprising a modification in a second T-cell expressed gene.
6. The modified cell of claim 1, wherein expression of TRAC or TRBC in the modified cell is modulated.
7. The modified cell of claim 1, wherein the modified cell is a T-cell.
8. The modified cell of claim 7, wherein the T-cell is a CD8+ T cell, a CD4+ T cell, a natural killer T cell, a regulatory T cell, or a stem cell memory T cell.
9. The modified cell of claim 7, wherein the T-cell is a CD8+ T cell.
10. The modified cell of claim 9, wherein the CD8+ T cell is a CD8+ naive T cell, a central memory T cell, or an effector memory T cell.
11. The modified cell of claim 1, wherein the modified cell is a lymphoid progenitor cell, a hematopoietic stem cell, a natural killer cell, or a dendritic cell.
12. The modified cell of claim 1, wherein the modification is within the first 500 bp of the coding sequence downstream from the start codon.
13. An *ex vivo* method of editing a cell, comprising contacting the cell with, or delivering to the cell, a composition comprising a non-viral RNP complex comprising:

    (a) a gRNA molecule comprising a targeting domain that is complementary to a target sequence on a target nucleic acid comprising the TRAC or TRBC gene, wherein the targeting

domain comprises a sequence that is the same, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450 ,49449, 49436, 49452, 49451, 50259, 50261, or 50356; and

(b) an *S. aureus* Cas9 polypeptide.

14. The *ex vivo* method of claim 13, wherein said contacting results in modification of the target sequence.

15. The *ex vivo* method of claim 13, wherein the target nucleic acid further comprises an NNGRR sequence.

16. An *ex vivo* method of editing a population of cells, comprising contacting the population of cells with a composition comprising a non-viral RNP complex comprising:

(a) a gRNA molecule comprising a targeting domain that is complementary to a target sequence on a target nucleic acid comprising the TRAC or TRBC gene, wherein the targeting domain comprises a sequence that is the same, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356; and

(b) an *S. aureus* Cas9 polypeptide or a nucleic acid encoding a Cas9 polypeptide, wherein at least 6% of the cells are edited.

17. The *ex vivo* method of claim 13 or claim 16, wherein the gRNA molecule comprises a targeting domain comprising a sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.

18. The method of claim 16, wherein the target nucleic acid further comprises an NNGRR sequence.

19. The method of claim 16, wherein the cells are T cells.

20. A population of modified cells, wherein the modified cells comprise a modification in the TRAC or TRBC gene made by delivering a non-viral RNP complex comprising an *S. aureus* Cas9 polypeptide and a gRNA molecule that targets TRAC or TRBC, wherein the gRNA molecule comprises a targeting domain comprising a sequence that is the same, or differs by no more than 3 nucleotides from, a targeting domain sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.

21. The population of modified cells of claim 20, wherein the gRNA molecule comprises a targeting domain comprising a sequence selected from any one of SEQ ID NOs: 49421, 49420, 49440, 49450, 49449, 49436, 49452, 49451, 50259, 50261, or 50356.